Index: 25551, ISSN 0025-0244
In four booklets per year
Responsible publisher: Vándor Ágnes (ügyvezető, Professional Publishing Hungary Kft.)
Sheet design: Szabó Zsuzsanna
Printing preparation: Professional Publishing Hungary Kft.
Printing production: Innovariant Nyomdaipari Kft.
Distributor: Magyar Posta Zrt., Hírlap Igazgatóság, Hírlap Értékesítési Osztály (1089 Budapest, Orczy tér 1.)
Available for subscription from the publisher: Professional Publishing Hungary Kft. (1037 Budapest, Montevideo u. 3/B)
Annual subscription fee: HUF 13,400 + VAT.
Free for MOT members.
Fekete Boglárka
Tel: +36 30 962 34 93
E-mail: elofizetes@pphmedia.hu
Index: 25551, ISSN 0025-0244
In four booklets per year
Responsible publisher: Ágnes Vándor (ügyvezető, Professional Publishing Hungary Kft.)
Sheet design: Zsuzsanna Szabó
Printing preparation: Professional Publishing Hungary Kft.
Printing production: Innovariant Nyomdaipari Kft.
Distributor: Magyar Posta Zrt., Hírlap Igazgatóság, Hírlap Értékesítési Osztály (1089 Budapest, Orczy tér 1.)
Available for subscription from the publisher: Professional Publishing Hungary Kft. (1037 Budapest, Montevideo u. 3/B)
Annual subscription fee: HUF 13,400 + VAT.
Free for MOT members.
Boglárka Fekete
Tel: +36 30 962 34 93
E-mail: elofizetes@pphmedia.hu
CSABA POLGÁR | National Institute of Oncology |
KRISZTINA BOGOS | National Korányi Institute of Pulmonology |
TIBOR MAJOR | National Institute of Oncology |
ANIKÓ MARÁZ | University of Szeged, Szent-Györgyi Albert Clinical Center, Oncotherapy Clinic |
ZOLTÁN NOVÁK | National Institute of Oncology |
ATTILA PATÓCS | Semmelweis University, Institute of Laboratory Medicine and National Institute of Oncology |
ÁKOS SÁVOLT | National Institute of Oncology |
ZOLTÁN TAKÁCSI-NAGY | National Institute of Oncology |
LÁSZLÓ DÁVID TÁRNOKI | Semmelweis University, Medical Imaging Clinic and National Oncology Institute |
PÉTER TENKE | Budapest Jahn Ferenc Dél-pest Hospital and Clinic and National Institute of Oncology |
ERIKA TÓTH | National Institute of Oncology |
JÓZSEF TÓVÁRI | National Institute of Oncology |
ANDREA LADÁNYI | National Institute of Oncology |
Publisher:
Professional Publishing Hungary Kft.
Postal address: H-1037 Budapest Montevideo u. 3/b.
Mailing address: H-1300 Budapest, Pf. 157.
Executive Director:
Ágnes Vándor
Email: vandor.agnes@pphmedia.hu
Division Director:
Judit Nagy
Phone: +36-30-922-0137
Fax: +36-1-430-4519
E.mail: nagy.judit@pphmedia.hu
Other data:
company registration number: 01-09-267066
Tax ID: 10875153-2-41
VAT: HU-10875153
Index: 25551
ISSN: 0025-0244
The paper publishes original dissertations in Hungarian or in English dealing with the practice and theory of oncology, which can be requested papers, professional recommendations, original publications, or so-called clinicopathological case reports.
The submitted manuscripts will be reviewed by the editorial board with the assistance of experts.
It is also possible to publish abstracts of conferences on Hungarian oncology, based on a preliminary consultation with the editorial board.
Manuscripts (word processing program: Microsoft Word 6.0 / 7.0) should be submitted electronically (by e-mail) (font: Calibri 12 p, line spacing 1.5, margin 2.5 cm) to the editor-in-chief and publisher email addresses:
polgar.csaba@oncol.hu, nagy.judit@pphmedia.hu
Download guide in PDF format
Hungarian Oncology (Magyar Onkológia) is the official quarterly journal of the Hungarian Society of Oncologists.
The journal publishes original Hungarian and English-language papers (with both Hungarian and English abstracts) dealing with the practice and theory of oncology, which may include invited references, professional recommendations, original publications, or clinicopathological case reports. Submitted manuscripts will be peer-reviewed by the Editorial Board with the assistance of experts (single anonymized review). Abstracts from national oncology conferences may also be published, subject to prior agreement with the Editorial Board.
Manuscrips should be submitted electronically (e-mail) in word-processed form (recommended word-processing software: Microsoft Word 6,0/7,0) (font: Calibri 12 p, line spacing 1.5, margin 2.5 cm) to the e-mail addresses of the Editor-in-Chief and the representative of the publisher: polgar.csaba@oncol.hu and nagy.judit@pphmedia.hu, respectively.
Attention! Only articles meeting the length limits will be accepted, which are (excluding title page and abstracts): for original research articles and case reports 3000 words + maximum 8 figures and/or tables and 50 references, for reviews 4500 words + maximum 8 figures and/or tables and 80 references. For each article type, any additional figures, tables and references will appear as supplementary information, linked to the electronic version of the article only.
The internationally accepted chemical name must be used for all medicines. The chemical composition and the name of the manufacturer must also be given.
Authors reporting a study that involved human participants (or their data or biological material) should include a statement confirming that the study was performed in accordance with the World Medical Association's Declaration of Helsinki, and in accordance with the relevant institutional and national guidelines, with the appropriate ethics committee's prior approval and informed written consent from all human subjects involved in the study (or when appropriate, the parent's or guardian's), including for publication of the results. To protect subject anonymity, identifying information should not be included in the manuscript unless such information is absolutely necessary for scientific purposes, and written informed consent has been granted by the subjects. The statement on approval by the national/regional research ethics committee or institutional review board must include the name of the ethics committee or institutional review board, as well as the project identification code and date of approval. If a study was granted exemption from requiring ethics approval or informed consent, the authors need to state the reasons for the exemption.
Studies involving regulated animals (vertebrates and higher invertebrates) must be performed ensuring humane treatment (maintenance and experimentation) of animals, in accordance with relevant institutional and national guidelines and regulations, and approved by an Institutional Animal Care and Use Committee or other appropriate review board; this should be confirmed in the manuscript. Studies involving animals should be conducted according to the European Union regulations on animal research (https://www.eara.eu/animal-research-law) and other internationally accepted standards such as the Guidelines for the Welfare and Use of Animals in Cancer Research (Br J Cancer 102:1555-1577, 2010), and are expected to comply with the three Rs principle (Replacement of animals by alternatives wherever possible; Reduction of the number of animals used; and Refinement of experimental conditions and procedures to minimize the harm to animals). The editors reserve the right to reject a manuscript if the research involves protocols that are inconsistent with commonly accepted norms for animal welfare.
Hungarian Oncology is the official journal of the Hungarian Society of Oncologists, published quarterly.
All rights reserved.
The Hungarian Oncology © 2024 by Hungarian Society of Oncologists and licensed under CC BY-NC-ND 4.0. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/